Development of a new fully human anti-CD20 monoclonal antibody for the treatment of B-cell malignancies

By Bornstein Gadi   Quéva Christophe   Tabrizi Mohammad   Abbema Anne   Chavez Carlos   Wang Ping   Foord Orit   Ahluwalia Kiran   Laing Naomi   Raja Sandhya   Wen Shenghua   Green Larry   Yang Xiaodong   Webster Carl   Stewart Ross   Blakey David  

Investigational New Drugs, Vol. 28, Iss. 5, 2010-10 ,pp. : 561-574

Springer Publishing Company

Access to resources Recommend Favorite

Targeting B Cells in SLE: The Experience with Rituximab Treatment (Anti-CD20)

By  

Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol. 6, Iss. 4, 2006-12 ,pp. : 345-350

Bentham Science Publishers

Access to resources Recommend Favorite

Cell Death Targeting Therapies in B Lymphoid Malignancies

By  

Current Drug Targets, Vol. 11, Iss. 7, 2010-07 ,pp. : 769-780

Bentham Science Publishers

Access to resources Recommend Favorite

Ofatumumab, a second-generation anti-CD20 monoclonal antibody, for the treatment of lymphoproliferative and autoimmune disorders

By Castillo Jorge   Milani Cannon   Mendez-Allwood Daniel  

Expert Opinion on Investigational Drugs, Vol. 18, Iss. 4, 2009-04 ,pp. : 491-500

Informa Healthcare

Access to resources Recommend Favorite

Drugs in clinical development for multiple sclerosis: focusing on anti-CD20 antibodies

By Gasperini Claudio   Haggiag Shalom   Ruggieri Serena  

Expert Opinion on Investigational Drugs, Vol. 22, Iss. 10, 2013-10 ,pp. : 1243-1253

Informa Healthcare

Access to resources Recommend Favorite